drugset
drugset / Trial / NCT00384072

Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women

NCT00384072 ↗

Phase 3 Completed 500 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.

Timeline

Start
2006-05
Primary completion
—
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg —

Indications

osteoporosis